Regeneron Set to Report Q3 2025 Earnings: Analysts Predict Dip Despite Strong Q2
Regeneron Pharmaceuticals, Inc. (REGN) is set to report its fiscal Q3 2025 earnings on Tuesday, October 28. The biotech giant, valued at a market cap of $59.1 billion, has seen its shares surge following a strong Q2 earnings report. However, analysts predict a dip in earnings for both the quarter and the fiscal year.
REGN's earnings of $12.89 per share in the previous quarter exceeded consensus estimates by a significant 60.5%. Despite this positive performance, shares have declined by 44.9% over the past 52 weeks, lagging behind both the S&P 500 Index and the Health Care Select Sector SPDR Fund. Looking ahead, analysts expect REGN to report a profit of $7.80 per share in Q3 2025, a decrease of 33.5% from the year-ago quarter. For fiscal 2025, earnings per share are projected to be $32.36, down 16.2% from fiscal 2024.
Wall Street analysts currently have a 'Moderate Buy' rating for REGN's stock, with a mean price target of $729.85. This implies a potential upside of 29.5% from current levels. REGN has a history of beating Wall Street's bottom-line estimates, having surpassed them in three of the last four quarters. The company's CEO, Leonard Schleifer, will likely provide further insights into REGN's performance and future prospects during the earnings call.
Regeneron Pharmaceuticals, Inc. is expected to report its fiscal Q3 2025 earnings on October 28. While recent quarters have shown strong earnings growth, analysts predict a decrease in earnings for both the quarter and the fiscal year. Despite this, Wall Street analysts maintain a positive outlook on REGN's stock, with a 'Moderate Buy' rating and a mean price target implying a 29.5% potential upside. Investors will be watching closely to see if REGN can continue its trend of beating earnings estimates.
